P625 Use of infliximab (Remicade®) for IBD within a patient support program: Positive perception of i.v. infusions from patient's perspective
J. Jones1, M. Borgaonkar2, J. Siffledeen3, D. Dajnowiec*4, P. Dyrda5
1Dalhousie University, QE II Health Sciences Center, Gastroenterology, Halifax, Canada, 2Memorial University, Gastroenterology, St. John's, Canada, 3University of Alberta, Gastroenterology, Edmonton, Canada, 4Janssen Canada, Medical Affairs, Toronto, Canada, 5Janssen Canada, Market Access, Toronto, Canada
In Canada, IBD patients treated with infliximab (IFX) are primarily managed through a nationwide patient support program (PSP) where a case coordinator manages treatment between the patient, physician and a network of infusion clinics. The aim of this study was to assess patients' experience of IFX therapy administered in this PSP.
In this nationwide, cross-sectional survey, patients currently receiving IFX within the PSP were given an information brochure to access a web-based survey (May 5-July 18, 2014) of demographic and disease characteristics, respondents' lifestyle and health ratings, and their perception of IV infusions before and after initiating therapy. The analysis was exploratory and descriptive; data collected was a self-reported ordinal scale (low to high, 1 - 10) with median (IQR) and mean (range) reported. The Wilcoxon signed-rank test was used for assessment of statistically significant differences in responses over time.
Of 10,000 brochures distributed in 192 clinics, there were 1,762 respondents (18%); >75% were treated for IBD. 49% were males, and median age was 41 (30-53) and 98% treated with IFX. 62% of respondents were employed, 8% unemployed, 11% retired, 9% on disability, 9% were students. 57% of respondents reported receiving therapy for >2 yrs, 18% for 1-2 yrs and 25% <12 mo. 73% of respondents were receiving their 1st biologic therapy. Regarding lifestyle, 57% of respondents stated that they travel for personal/work reasons and 76% of all responders self-categorized as living a busy/active lifestyle. Median health rating was high 8(6-9), with higher values observed for patients enrolled in the program for longer periods of time (p<0.0001). Changes in the initial vs. current patient impressions on specific attributes of the program were notably positive. Experience of having multiple infusions revealed how worthwhile the time commitment was and hence improved patients' perception on of the value of the time required to complete an infusion. The overall perception of IV infusions was increased as well; the majority of patients rated it as 5 prior to starting therapy vs. 8 after multiple infusions (p<0.0001). Change in perception of IV infusions varied based on the initial rating with over 90% of patients increasing their rating from 1-6 pts after undergoing infusions.
While this study is subject to a strong selection bias, we found that these patients lead busy/active lifestyles, see the time commitment of IV treatment as worthwhile, have a positive experience at the clinics and report significant improvements in their perception of IV infusion. Further studies on this topic are warranted.